ChargePoint Technology and STERIS collaborate to offer fully validated sterile transfer solution
Sterile transfer solutions without compromising operational efficiency.
Powder containment and sterile transfer solutions experts, ChargePoint Technology, has entered into a collaboration with STERIS, a provider of infection prevention and other procedural products and services, to offer a unique and integrated solution for sterile product transfer.
Integrating ChargePoint’s AseptiSafe Bio Transfer Valve with the STERIS VHP Biodecontamination Systems provides users with a fully validated solution for the sterile transfer of drug substances and drug products during biopharmaceutical manufacturing.
As regulations around sterile/aseptic processing continue to expand, many manufacturers are looking for sterile transfer solutions that do not compromise operational efficiency.
The ChargePoint split butterfly valve (SBV) technology enables contained transfers into a manufacturing process, providing sterility assurance during aseptic processing. The technology reduces the need for operator intervention and for cleaning and validating large areas which, in turn, minimizes downtime and improves efficiencies during manufacturing.Christian Dunne, head of sterile solutions at ChargePoint Technology, said: “Combining expertise from the two teams ensures that we are able to offer customers across the globe a unique and efficient solution to one of today’s drug manufacturing challenges.”
The AseptiSafe Bio Transfer Valve uses an enhanced decontamination step, exposing the SBV discs to vaporized hydrogen peroxide (VHP) gas within a sealed chamber. This provides a validated 6-log reduction in bioburden during the drug substance transfer process and removes the need for high-grade cleanroom environments around the process.
The STERIS VHP generators provide an all-in-one system unit for biodecontamination in medical, biological and pharmaceutical facilities. The generators utilise STERIS Vaprox Hydrogen Peroxide Sterilant to achieve dry, low-temperature biodecontamination within sealed enclosures for maximum biodecontamination.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance